U.S., May 31 -- ClinicalTrials.gov registry received information related to the study (NCT06997081) titled 'ERd Combination Treatment in Newly Diagnosed Multiple Myeloma' on May 21.
Brief Summary: The purpose of this study is to determine the effects that Elranatamab in combination with Lenalidomide and Dexamethasone has on participants that have been newly diagnosed with Multiple Myeloma.
Study Start Date: Aug. 01, 2025
Study Type: INTERVENTIONAL
Condition:
Multiple Myeloma
Intervention:
DRUG: Lenalidomide
Participants will receive 25mg of Lenalidomide orally on Days 2-21 of Cycle 1, then 25 mg by mouth on Days 1-21 of the remaining cycles.
DRUG: Dexamethasone
Participants will receive 20mg of Dexamethasone orally on Days 1, 3, 8...